Latest rheumatoid arthritis Stories

MOUNTAIN VIEW, Calif., Oct. 10, 2012 /PRNewswire/ -- The treatment beyond standard of care for ankylosing spondylitis (AS) pharmacotherapeutics currently consists of a single drug class - tumor necrosis factor (TNF) inhibitors. This unavailability of alternative treatment represents an underserved and potentially significant market that is waiting for exploration. New analysis from Frost & Sullivan's (http://www.lifesciences.frost.com) United States Market for Ankylosing...

Michael Harper for redOrbit.com – Your Universe Online Rheumatoid arthritis research has just had an advance as scientists from the Northwestern University Feinberg School of Medicine have finally found an animal which has the same response to the disease as people: Humanized mice. This discovery will improve arthritis research, giving scientists an accurate model with which to try new drugs and procedures in an effort to treat and cure the disease. The research team, lead by senior...

Scientists from the Florida campus of The Scripps Research Institute have developed a novel technology that can identify, in animal models, potential biomarkers of ulcerative colitis, a type of inflammatory bowel disease that affects the lining of the colon. The study was published October 3, 2012, in the Journal of the American Chemical Society. The new research focuses on the protein arginine deiminases (PAD), which have been implicated in a number of diseases, including cancer,...

A study that included more than 45,000 residents of Sweden with rheumatoid arthritis finds that individuals with this disease had an associated higher risk of venous thromboembolism (a blood clot that forms within a vein), and that this elevated risk was stable for 10 years after the time of diagnosis, according to a study in the October 3 issue of JAMA. "Recent reports suggest that rheumatoid arthritis (RA) may be a risk factor for venous thromboembolism (VTE), particularly in conjunction...

HORSHAM, Pa., Oct. 1, 2012 /PRNewswire/ -- Janssen Biotech, Inc. ("Janssen") announced today that it has entered into a license agreement with Astellas Pharma Inc. ("Astellas") for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor. ASP015K is currently in Phase 2b development as a once-daily oral treatment for moderate-to-severe rheumatoid arthritis (RA), following a successful Phase 2a study...

DEERFIELD, Ill., Oct. 1, 2012 /PRNewswire/ -- Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that it has completed the expansion of its sales force from 80 to 150 representatives. This expansion will allow increased reach and frequency of calls on physician targets for its lead product DUEXIS(®) (ibuprofen and famotidine), which is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper...

Lee Rannals for redOrbit.com - Your Universe Online Eating cherries may lower your risk of a certain type of inflammatory arthritis attack, according to a study published in Arthritis & Rheumatism. Researchers found that patients with gout who consumed cherries over a two-day period showed a 35 percent lower risk of having attacks compared to those who did not eat the fruit. The scientists recruited 633 gout patients for the study, and followed them for a one year period....

DEERFIELD, Ill., Sept. 28, 2012 /PRNewswire/ -- Horizon Pharma, Inc. (NASDAQ: HZNP), announced today that it has received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/403,930 and U.S. Application Serial No. 13/403,923 both entitled "Stable Compositions of Famotidine and Ibuprofen" with claims that cover DUEXIS(®) (ibuprofen and famotidine) tablets. DUEXIS is indicated for the relief of signs and symptoms...

Research carried out at The University of Manchester has found further evidence that a simple solution, which is already used in IV drips, is an effective treatment for reducing inflammation. The researchers also identified that hypertonic solution, which is a solution with an elevated concentration of salt, can ease inflammation purely through bathing in it – proving the Victorians were right to visit spa towns to "take the waters" for ailments like rheumatoid arthritis. The research...

HORSHAM, Pa., Sept. 18, 2012 /PRNewswire/ -- Janssen Biotech, Inc. announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of an investigational intravenous formulation of the anti-tumor necrosis factor (TNF)-alpha SIMPONI(®) (golimumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). An estimated 1.5 million Americans are living with RA,[1] a chronic...